sepsis. Sepsis due to other Gram-negative organisms
Conditions
Interventions
Intervention 1: patients devided in 2 groups and in one group (high dose group) amikacin by dose of 25 mg/kg based on IBW will be administered to the patients. serum and urine samples will be collecte
es will be collected on baseline and days 3,5,7, and 10 for analysis.
Treatment - Drugs
patients devided in 2 groups and in one group (high dose group) amikacin by dose of 25 mg/kg based on IBW will be administered to the patients. serum and urine samples will be collected on baseline an
In second group ( standard dose group) amikacin by dose of 15 mg/kg based on IBW will be administered for the patients for 10 days and serum and urine sampl
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: age equal to or more than 65; serum creatinin equal to or less than 1.2 or estimated GFR equal to or more than 40 ml/min; sepsis with gram negative or unknown microorganism in geriatric patients addmited in ICU and need for an aminoglycoside and no history of aminoglycoside administration in the last 30 days. Exclusion criteria: age less than 65; aminoglycoside administration in the last 30 days; BMI more than 35; Allergy to aminoglycosides; amikacin administration less than 5 days; trouph levels more than 10 mcg/ml; need for amikacin dose adjustment during study period; neoplasm diagnisis with chemotherapy or radiotherapy history; viral hepatitis; moderate to severe renal failure considering normal decline in GFR with aging ( Scr more than 1.2); life expectancey less than 48 hours and APACHE II score more than 35.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Akutre kidney injury incidence. Timepoint: baseline and during drug administration on days: 3, 5 , 7, 10. Method of measurement: measurment of AKI biomarkers and serum creatinine. | — |
Secondary
| Measure | Time frame |
|---|---|
| Survival after 28 days post intervention in two groups. Timepoint: 28 days after initiation of study. Method of measurement: report of survival or mortality on day 28. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKourosh Sadeghi
Tehran University of Medical Sciences
Outcome results
None listed